Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus standard of care for active lupus nephritis
NL-OMON47929Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Belimumab plus standard of care, Placebo plus standard of care and Open-label belimumab phase (3 arms). Primary endpoint: Primary Efficacy Renal Response at Week 104. Started Feb 2016; status: active, not recruiting.
02
Drugs
belimumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON47929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47929.